Scandion Oncology A/S (ST:SCOL) — Stock Price
Scandion Oncology A/S (ST:SCOL) is currently trading at Skr0.00 SEK, up 0.00% today. Over the past 52 weeks, shares have ranged between Skr0.00 and Skr0.00. This page tracks Scandion Oncology A/S's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Scandion Oncology A/S (SCOL) total market value.
Scandion Oncology A/S (SCOL) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Scandion Oncology A/S's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daily price history is not currently available for Scandion Oncology A/S.
Scandion Oncology A/S Income Statement — Revenue, Profit & Earnings by Year
Scandion Oncology A/S's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | Skr19.32 Million | Skr31.85 Million | Skr65.06 Million | Skr47.71 Million | Skr21.67 Million |
| SG&A | Skr8.04 Million | Skr13.95 Million | Skr7.01 Million | Skr3.14 Million | Skr14.46 Million |
| Total Operating Expenses | Skr41.02 Million | Skr45.36 Million | Skr80.17 Million | Skr55.37 Million | Skr22.89 Million |
| Operating Income | Skr-41.02 Million | Skr-45.36 Million | Skr-80.17 Million | Skr-55.37 Million | Skr-22.89 Million |
| EBITDA | — | Skr-45.53 Million | Skr-80.82 Million | Skr-56.10 Million | Skr-22.85 Million |
| EBIT | — | Skr-45.80 Million | Skr-81.70 Million | Skr-56.70 Million | Skr-23.13 Million |
| Interest Expense | Skr5.00K | Skr38.00K | Skr495.00K | Skr767.00K | Skr42.00K |
| Income Before Tax | Skr-40.91 Million | Skr-44.70 Million | Skr-82.20 Million | Skr-57.21 Million | Skr-20.65 Million |
| Income Tax Expense | — | Skr5.50 Million | Skr-5.50 Million | Skr-5.51 Million | Skr-4.38 Million |
| Net Income | Skr-36.66 Million | Skr-39.20 Million | Skr-76.70 Million | Skr-51.70 Million | Skr-16.27 Million |
Scandion Oncology A/S Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Scandion Oncology A/S's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Skr18.28 Million | Skr34.56 Million | Skr89.40 Million | Skr116.22 Million | Skr186.41 Million |
| Total Current Assets | Skr18.14 Million | Skr33.66 Million | Skr86.86 Million | Skr114.30 Million | Skr186.12 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Skr807.00K | — | — | Skr7.52 Million | Skr5.80 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | Skr2.26 Million | Skr1.60 Million | Skr448.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr10.01 Million | Skr3.44 Million | Skr19.07 Million | Skr11.68 Million | Skr30.54 Million |
| Total Current Liabilities | Skr10.01 Million | Skr3.44 Million | Skr18.25 Million | Skr11.09 Million | Skr30.03 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | Skr-12.62 Million | Skr-26.02 Million | Skr-76.01 Million | Skr-104.49 Million | Skr-5.50 Million |
| Total Stockholder Equity | Skr8.27 Million | Skr31.12 Million | Skr70.33 Million | Skr104.54 Million | Skr155.87 Million |
| Retained Earnings | Skr-241.54 Million | Skr-204.88 Million | Skr-165.67 Million | Skr-88.97 Million | Skr-37.65 Million |
Scandion Oncology A/S Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Scandion Oncology A/S generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-27.52 Million | Skr-50.67 Million | Skr-69.44 Million | Skr-49.80 Million | Skr-17.45 Million |
| Capital Expenditures | Skr0.00 | Skr0.00 | Skr414.00K | Skr318.00K | Skr46.00K |
| Free Cash Flow | Skr-27.52 Million | Skr-50.67 Million | Skr-69.86 Million | Skr-50.12 Million | Skr-17.50 Million |
| Investing Cash Flow | Skr175.00K | Skr288.00K | Skr-389.00K | Skr-485.00K | Skr-46.00K |
| Financing Cash Flow | Skr13.51 Million | Skr-705.00K | Skr41.73 Million | Skr150.18 Million | Skr7.89 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | Skr0.00 | Skr-52.00K | Skr379.00K | Skr865.00K |
| Depreciation | Skr445.00K | Skr969.00K | Skr882.00K | Skr604.00K | Skr36.00K |
| Change in Cash | Skr-13.84 Million | Skr-51.09 Million | Skr-28.11 Million | Skr99.90 Million | Skr-9.61 Million |
Scandion Oncology A/S Earnings History — EPS Actual vs. Analyst Estimates
Track Scandion Oncology A/S's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 20, 2026 | — | — | — |
| Mar 10, 2026 | — | — | — |
| Aug 28, 2025 | — | — | — |
| May 22, 2025 | — | — | — |
| Feb 28, 2025 | -0.10 | — | — |
| Nov 11, 2024 | -0.04 | — | — |
| Aug 29, 2024 | -0.05 | — | — |
| May 22, 2024 | -0.16 | — | — |